Fig 1.
Representative images for the modified LANZA score.
These figures indicate representative images of the modified LANZA score.
Table 1.
Baseline characteristics of this study.
Table 2.
Univariate analyses for comparisons between the modified LANZA score and each independent variable.
Table 3.
A multivariate analysis to determine the relationship between the modified LANZA score and independent risk factors.
Fig 2.
A comparison of the modified LANZA score based on the NSAIDs and PSL treatment status.
Values are shown as the mean±SEM (standard error of the mean). Data were analyzed using Tukey-Kramer test, **p<0.01. PSL, prednisolone; NSAIDs, non-steroidal anti-inflammatory drugs.
Fig 3.
A comparison of the modified LANZA scores between those treated with COX-2-selective inhibitors and those treated with non-selective COX-1 and COX-2 inhibitors.
(a) A comparison of the modified LANZA scores between patients treated with and without NSAIDs. (b) A comparison of the modified LANZA score between patients treated with COX-2-selective inhibitors and non-selective COX-1 and COX-2 inhibitors. Value are shown as the mean±SEM. Data were analyzed using a t-test, *p<0.05, **p<0.01. NSAIDs, non-steroidal anti-inflammatory drugs; COX, cyclooxygenase. Celecoxib, etodolac and meloxicam are COX-2-selective NSAIDs.